Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Celldex Therapeutics (CLDX) Accumulated Depreciation & Amortization (2016 - 2025)

Celldex Therapeutics (CLDX) has 14 years of Accumulated Depreciation & Amortization data on record, last reported at $23.5 million in Q4 2024.

  • For Q4 2024, Accumulated Depreciation & Amortization rose 4.82% year-over-year to $23.5 million; the TTM value through Dec 2024 reached $23.5 million, up 4.82%, while the annual FY2024 figure was $23.5 million, 4.82% up from the prior year.
  • Accumulated Depreciation & Amortization reached $23.5 million in Q4 2024 per CLDX's latest filing, up from $22.4 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $23.5 million in Q4 2024 and bottomed at $21.1 million in Q4 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $22.0 million, with a median of $21.6 million recorded in 2022.
  • Peak YoY movement for Accumulated Depreciation & Amortization: fell 25.23% in 2020, then grew 4.82% in 2024.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $21.2 million in 2020, then fell by 0.52% to $21.1 million in 2021, then grew by 2.37% to $21.6 million in 2022, then grew by 3.51% to $22.4 million in 2023, then rose by 4.82% to $23.5 million in 2024.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $23.5 million in Q4 2024, $22.4 million in Q4 2023, and $21.6 million in Q4 2022.